Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2017-05-19 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
IdeS selected for EMA Priority Medicines (PRIME) scheme
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 19, 2017. It announces a specific regulatory/development milestone: IdeS being selected for the EMA's Priority Medicines (PRIME) scheme. This is an announcement regarding a drug development update and regulatory interaction, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal shareholder communication (like DEF 14A or AGM-R). While it contains some business context, its primary function is to disseminate time-sensitive, non-financial operational news to the public and investors. This type of announcement, which is not covered by the more specific codes (like DIV, CAP, MANG, DIRS), falls best under the general category for regulatory/operational announcements, which is RNS (Regulatory Filings), or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the press release format announcing a regulatory milestone, RNS is the most appropriate general fit, as it is a regulatory/operational disclosure that doesn't fit the other specific categories.
2017-05-19 English
Emission och återköp av C-aktier för incitamentsprogram
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated April 27, 2017, titled "Emission och återköp av C-aktier för incitamentsprogram" (Issuance and repurchase of C-shares for incentive program). It details a decision by the board to issue and immediately repurchase C-shares as part of a performance-based incentive program (LTIP 2016). This action directly relates to changes in the company's capital structure, specifically involving share issuance, repurchase, and subsequent conversion to common stock to fulfill obligations under an employee plan. This aligns best with the 'Share Issue/Capital Change' category (SHA), as it involves the issuance and subsequent transaction of shares related to capital structure management, rather than just a general financing update (CAP) or a simple transaction in own shares (POS), as it is tied to a specific incentive scheme requiring issuance and repurchase steps.
2017-04-27 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Hansa Medical covering the period January to March 2017. It contains detailed financial tables (income statement, cash flow, equity), management commentary ('Vd har ordet'), business overviews, and pipeline status. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-04-26 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January –March 2017' and contains comprehensive financial data, including a financial summary for the first quarter, operating profit/loss, net profit/loss, and earnings per share. It also includes a CEO statement, business overview, and detailed pipeline information. Since it covers a period shorter than a full fiscal year and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. Q1 2017
2017-04-26 English
Annual Report 2016
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2016' (Annual Report 2016) for Hansa Medical. It contains a comprehensive overview of the company's activities, financial statements (Räkningar), management report (Förvaltningsberättelse), auditor's report (Revisionsberättelse), and corporate governance information. It is a full-length annual report, not an announcement or summary. FY 2016
2017-04-26 Swedish
Annual Report 2016
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual report 2016' and contains comprehensive sections including a CEO comment, strategic overview, detailed financial statements, notes, auditor's report, and corporate governance report. It covers the full fiscal year and provides substantive financial data, fitting the definition of an Annual Report (10-K). FY 2016
2017-04-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.